Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging

Brain

Volumn 120, Issue 7, 1997, Pages 1149-1161

  Silver, N C ^a   Good, C D ^b   Barker, G J ^a   MacManus, D G ^a   Thompson, A J ^a   Moseley, I F ^a   McDonald, W I ^a   Miller, D H ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Gadolinium enhancement; Magnetic resonance imaging; Magnetization transfer contrast; Multiple sclerosis

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM PENTETATE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; HEADACHE; HOT FLUSH; HUMAN; IMAGING; MULTIPLE SCLEROSIS; MUSCLE SPASM; NERVE LESION; NUCLEAR MAGNETIC RESONANCE IMAGING; PENIS DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; URINE INCONTINENCE; VOMITING; XEROSTOMIA;

EID: 0030754518     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/120.7.1149     Document Type: Article

References (43)

1. Balaban RS, Ceckler TL. Magnetization transfer contrast in magnetic resonance imaging. [Review]. Magn Reson Q 1992; 8: 116-37.
2. Filippi M, Campi A, Martinelli V, Colombo B, Yousry T, Canal N, et al. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1995; 59: 540-4.
3. Filippi M, Yousry T, Campi A, Kandziora C, Colombo B, Voltz R, et al. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS. Neurology 1996a; 46: 379-84.
4. Filippi M, Capra R, Campi A, Colombo B, Prandini F, Marcianò N, et al. Triple dose of gadolinium-DTPA and delayed MRI in patients with benign multiple sclerosis. J Neurol Neurosurg Psychiatry 1996b; 60: 526-30.
5. Filippi M, Yousry T, Horsfield MA, Alkadhi H, Rovaris M, Campi A, et al. A high-resolution three-dimensional T1-weighted gradient echo sequence improves the detection of disease activity in multiple sclerosis. Ann Neurol 1996c; 40: 901-7.
6. Filippi M, Barkhof F, Bressi S, Yousry TA, Miller DH. Interrater variability in reporting enhancing lesions present on standard and triple dose gadolinium scans in patients with multiple sclerosis (MS) [abstract]. J Neurol 1996d; 243 Suppl 2: S70
7. Finelli DA, Hurst GC, Gullapali RP, Bellon EM. Improved contrast of enhancing brain lesions on postgadolinium, T1-weighted spin echo images with use of magnetization transfer. Radiology 1994; 190: 553-9.
8. Frank JA, Stone LA, Smith ME, Albert PS, Maloni H, McFarland HF. Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: implications for treatment trials. Ann Neurol 1994; 36 Suppl: S86-90.
9. Gallagher HL, MacManus DG, Webb SL, Miller DH. A reproducible repositioning method for serial magnetic resonance imaging studies of the brain in treatment trials for multiple sclerosis. Magn Reson Imag 1997. In press.
10. Gonzalez-Scarano F, Grossman RI, Galetta S, Atlas SW, Silberberg DH. Multiple sclerosis disease activity correlates with gadolinium-enhanced magnetic resonance imaging. Ann Neurol 1987; 21: 300-6.
11. Haustein J, Laniado M, Niendorf H-P, Louton T, Beck W, Planitzer J, et al. Triple-dose versus standard-dose gadopentetate dimeglumine: a randomized study in 199 patients. Radiology 1993; 186: 855-60.
12. Hawkins CP, Munro PMG, MacKenzie F, Kesselring J, Tofts PS, du Boulay EPGH, et al. Duration and selectivity of blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers. Brain 1990; 113: 365-78.
13. Katz D, Taubenberger JK, Cannella B, McFarlin DE, Raine CS, McFarland HF. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 1993; 34: 661-9.
14. Kermode AG, Thompson AJ, Tofts P, MacManus DG, Kendall BE, Kingsley DPE, et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Brain 1990a; 113: 1477-89.
15. Kermode AG, Tofts PS, Thompson AJ, MacManus DG, Rudge P, Kendall BE, et al. Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. Neurology 1990b; 40: 229-35.
16. Kidd D, Thompson AJ, Kendall BE, Miller DH, McDonald WI. Benign form of multiple sclerosis: MRI evidence for less frequent and less inflammatory disease activity. J Neurol Neurosurg Psychiatry 1994; 57: 1070-2.
17. Kidd D, Thorpe JW, Kendall BE, Barker GJ, Miller DH, McDonald WI, et al. MRI dynamics of brain and spinal cord in progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1996; 60: 15-9.
18. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
19. Losseff NA, Kingsley DPE, McDonald WI, Miller DH, Thompson AJ. Clinical and magnetic resonance imaging predictors of disability in primary and secondary progressive multiple sclerosis. Multiple Sclerosis 1996a; 1: 218-22.
20. Losseff NA, Kidd D, McDonald WI, Miller DH, Thompson AJ. The predictive value of short term MRI activity for long term disability in relapsing-remitting multiple sclerosis [abstract]. Eur J Neurol 1996b; 3 Suppl 4: 11.
21. Mathews VP, King JC, Elster AD, Hamilton CA. Cerebral infarction: effects of dose and magnetization transfer saturation at gadolinium-enhanced MR imaging. Radiology 1994; 190: 547-52.
22. McLean BN, Zeman AZ, Barnes D, Thompson EJ. Patterns of blood-brain barrier impairment and clinical features in multiple sclerosis. J Neurol Neurosurg Psychiatry 1993; 56: 356-60.
23. Mehta RC, Pike GB, Haros SP, Enzmann DR. Central nervous system tumor, infection, and infarction: detection with gadolinium-enhanced magnetization transfer MR imaging. Radiology 1995; 195: 41-6.
24. Miller DH. Magnetic resonance in monitoring the treatment of multiple sclerosis. [Review]. Ann Neurol 1994; 36 Suppl: S91-4.
25. Miller DH, Barkhof F, Nauta JJP. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 1993; 116: 1077-94.
26. Miller DH, Albert PS, Barkhof F, Francis G, Frank JA, Hodgkinson S, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 1996; 39: 6-16.
27. Nesbit GM, Forbes GS, Scheithauer BW, Okazaki H, Rodriguez M. Multiple sclerosis: histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy. Radiology 1991; 180: 467-74.
28. Niendorf HP, Alhassan A, Haustein J, Clauss W, Cornelius I. Safety and risk of gadolinium-DTPA: extended clinical experience after more than 5,000,000 applications. Adv MRI Contrast 1993; 2: 12-9.
29. Poser CM, Paty D, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
30. Revesz T, Kidd D, Thompson AJ, Barnard RO, McDonald WI. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain 1994; 117: 759-65.
31. Rodriguez M, Scheithauer BW, Forbes G, Kelly PJ. Oligodendrocyte injury is an early event in lesions of multiple sclerosis [see comments]. Mayo Clin Proc 1993; 68: 627-36. Comment in: Mayo Clin Proc 199?; 6?: 000-0.
32. Rodriguez M, Scheithauer BW, Forbes G, Kelly PJ. Oligodendrocyte injury is an early event in lesions of multiple sclerosis [see comments]. Mayo Clin Proc 1993; 68: 627-36. Comment in: Mayo Clin Proc 199?; 6?: 000-0.
33. Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, et al. Clinical outcomes assessment in multiple sclerosis. Ann Neurol 1996; 40: 469-79.
34. Runge VM, Kirsch JE, Thomas GS. High-dose applications of gadolinium chelates in magnetic resonance imaging. Magn Reson Med 1991; 22: 358-63.
35. Smith ME, Stone LA, Albert PS, Frank JA, Martin R, Armstrong M, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol 1993; 33: 480-9.
36. Tanttu JI, Sepponen RE, Lipton MJ, Kuusela T. Synergistic enhancement of MRI with Gd-DTPA and magnetization transfer. J Comput Assist Tomogr 1992; 16: 19-24.
37. Thompson AJ, Kermode AG, Wicks D, MacManus DG, Kendall BE, Kingsley DPE, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991; 29: 53-62.
38. Thompson AJ, Miller D, Youl B, MacManus D, Moore S, Kingsley D, et al. Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology 1992; 42: 60-3.
39. Tofts PS. Optimal detection of blood-brain barrier defects with Gd-DTPA MRI-the influences of delayed imaging and optimised repetition time. Magn Reson lmag 1996; 14: 373-80.
40. Willoughby EW, Grochowski E, Li DKB, Oger J, Kastrukoff LF, Paty DW. Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients. Ann Neurol 1989; 25: 43-9.
41. Wolansky LJ, Bardini JA, Cook SD, Zimmer AE, Sheffet A, Lee H-J. Triple-dose versus single-dose gadoteridol in multiple sclerosis patients. J Neuroimaging 1994; 4: 141-5.
42. Wolff SD, Balaban RS. Magnetization transfer contrast (MTC) and tissue water proton relaxation in vivo. Magn Reson Med 1989; 10: 135-44.
43. Yuh WTC, Fisher DJ, Engelken JD, Greene GM, Sato Y, Ryals TJ, et al. MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol. Radiology 1991; 180: 485-91.